Enterprise Value to EBITDA (EV/EBITDA)
Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
DexCom Inc., EBITDA calculation
US$ in thousands
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
| Item | Description | The company |
|---|---|---|
| EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | DexCom Inc. EBITDA decreased from 2020 to 2021 but then increased from 2021 to 2022 exceeding 2020 level. |
Enterprise Value to EBITDA Ratio, Current
DexCom Inc., current EV/EBITDA calculation, comparison to benchmarks
| Selected Financial Data (US$ in thousands) | |
| Enterprise value (EV) | 30,908,961) |
| Earnings before interest, tax, depreciation and amortization (EBITDA) | 565,300) |
| Valuation Ratio | |
| EV/EBITDA | 54.68 |
| Benchmarks | |
| EV/EBITDA, Competitors1 | |
| Abbott Laboratories | 19.94 |
| Cigna Group | 11.05 |
| CVS Health Corp. | 7.03 |
| Elevance Health Inc. | 8.42 |
| Humana Inc. | 5.39 |
| Intuitive Surgical Inc. | 74.98 |
| Medtronic PLC | 16.19 |
| UnitedHealth Group Inc. | 16.07 |
| EV/EBITDA, Sector | |
| Health Care Equipment & Services | 15.22 |
| EV/EBITDA, Industry | |
| Health Care | 14.98 |
Based on: 10-K (reporting date: 2022-12-31).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
DexCom Inc., historical EV/EBITDA calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Enterprise value (EV)1 | 41,016,904) | 38,537,513) | 38,474,254) | 22,641,443) | 12,793,858) | |
| Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 565,300) | 376,200) | 376,800) | 213,200) | (74,700) | |
| Valuation Ratio | ||||||
| EV/EBITDA3 | 72.56 | 102.44 | 102.11 | 106.20 | — | |
| Benchmarks | ||||||
| EV/EBITDA, Competitors4 | ||||||
| Abbott Laboratories | 15.85 | 17.42 | 25.99 | 21.70 | — | |
| Cigna Group | 8.88 | 9.06 | 6.31 | 8.42 | — | |
| CVS Health Corp. | 12.42 | 10.41 | 8.56 | 9.43 | — | |
| Elevance Health Inc. | 10.26 | 10.05 | 7.57 | 9.05 | — | |
| Humana Inc. | 11.59 | 11.22 | 6.91 | 9.30 | — | |
| Intuitive Surgical Inc. | 41.52 | 44.54 | 59.12 | 37.53 | — | |
| Medtronic PLC | 14.99 | 24.41 | 17.92 | 16.01 | — | |
| UnitedHealth Group Inc. | 15.11 | 17.39 | 13.39 | 13.82 | — | |
| EV/EBITDA, Sector | ||||||
| Health Care Equipment & Services | 13.86 | 15.20 | 12.74 | 12.95 | — | |
| EV/EBITDA, Industry | ||||||
| Health Care | 13.35 | 13.31 | 16.61 | 14.16 | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
3 2022 Calculation
EV/EBITDA = EV ÷ EBITDA
= 41,016,904 ÷ 565,300 = 72.56
4 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| EV/EBITDA | Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. | DexCom Inc. EV/EBITDA ratio increased from 2020 to 2021 but then decreased significantly from 2021 to 2022. |